GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

Use of belimumab prior to vs after initiating immunosuppressants was linked to faster OGC tapering and fewer disease flares among patients with SLE.

Although obinutuzumab has not yet received FDA approval in lupus nephritis, findings from a recent survey conducted by ...

Discover how Obexelimab's unique B-cell inhibition and pivotal Phase 3 IgG4 results could drive Zenas BioPharma, Inc.'s potential. Click for more on ZBIO stock.

Havas Delivers Solid Performance in the First Half of 2025, With Organic Growth of +2.3%, and Adjusted EBIT up 8.3% Year-on-Year ...

GSK’s Belimumab Study: A Potential Game-Changer for Early SLE Treatment Trump administration mulls charging patent holders 1%-5% fee, WSJ reports ...

GSK reports Q2 core EPS 46.5p, up 15% at CER GSK revises FY25 guidance at CER, with core EPS towards top end 6%-8% GSK’s Belimumab Study: A Potential Game-Changer for Early SLE Treatment ...

Manufacturing GSK telegraphs 150 layoffs amid plan to transfer vaccine manufacturing from Massachusetts site By Fraiser Kansteiner Jul 22, 2025 8:53am GSK drug manufacturing vaccine manufacturing ...

Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new medicines, including a promising candidate for a chronic lung condition ...

Chris Ratcliffe/Bloomberg British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March 2026, the company said in a notice to the state.